Replies to post #439710 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

hankmanhub, I am guessing that they had a peak at some of the patients who had pseudo-progressed earlier but had survived a long time thereafter and than established their identity as Treatment patients. That may have been a small minority of the 331 patients. They were still blinded with respect to the overwhelming majority of the patients.

[skitahoe]

Hank,

Given the fact that most control patients had also crossed over, even though blinded as to who had what treatment, it would have been pretty clear that lots of people were living longer than anticipated for the SOC alone. The trial is officially blinded until you know what treatment each patient received, that didn't occur until the trial was data locked, but data, like what Dr. Liau reported on the Top 100 at SNO in 2019 should be easy to see that many in the trial were living 5 years or more, far more than would have been the case with all on the SOC.

There were really not many patients in the trial that didn't cross over. It's just speculation by me, but I believe those who didn't either passed away, or were to sick to do so, by the time they had the opportunity to do so. If I'm right, virtually no patients will be among those who're still alive that didn't receive the vaccine either up front or on crossing over.

Gary

[biosectinvestor]

The company did not determine that and the blind was maintained. The regulator determined that upon the safety review. The placebo arm was getting the drug late and likely not having the same incredible results as the treatment arm. The blind was never lifted, and could not be lifted. All a theory, won’t know until we know.